Investment company Shenzhen Investment Holdings led a $147m Series C round in Hinova Pharmaceuticals, a Chengdu-based drug research firm, with participation from Huarong Rongde Asset Management, Hangzhou Tigermed, and Sinopharm-CICC Capital. The financing capital will be used to support multi-center clinical trials and to commercialize the firm’s drug candidates locally and internationally.